Loading…

SUSCEPTIBILITIES OF BACTERIA ISOLATED FROM PATIENTS WITH LOWER RESPIRATORY INFECTIOUS DISEASES TO ANTIBIOTICS(2002)

From October 2002 to September 2003, we collected the specimen from 476 patients with lower respiratory tract infections in 16 institutions in Japan, and investigated the susceptibilities of isolated bacteria to various antibacterial agents and patients' characteristics. Of 584 strains that wer...

Full description

Saved in:
Bibliographic Details
Published in:Japanese journal of antibiotics 2004/06/25, Vol.57(3), pp.213-245
Main Authors: SHIMADA, KAORU, NAKANO, KUNIO, IGARI, JUN, OGURI, TOYOKO, IDEMOTO, HIDEO, MORI, TAKESHI, YOKOUCHI, HIROSHI, YAMAMOTO, MAKOTO, INOUE, HIROSHI, NAKADATE, TOSHIHIDE, SUWABE, AKIRA, OKADA, SHINJI, ASHINO, YUGO, GEJYO, FUMITAKE, OKADA, MASAHIKO, AOKI, NOBUKI, KITAMURA, NOBUKO, SUZUKI, YASUTOSHI, KARASAWA, YASUO, NADATA, KOICHIRO, NADATANI, TATSUO, INAGAWA, HIROKO, KUDO, KOUICHIRO, KOBAYASHI, NOBUYUKI, TANAKA, TSUKASA, KOBAYASHI, HIROYUKI, GOTO, HAJIME, KAWAI, SHIN, TAKEDA, HIDENORI, SUMITOMO, MIDORI, MATSUSHIMA, TOSHIHARU, NIKI, YOSHIHITO, KOHNO, SHIGERU, MIYAZAKI, YOSHITUGU, YANAGIHARA, KATSUNORI, HIRAKATA, YOICHI, MATSUDA, JUNICHI, NASU, MASARU, HIRAMATSU, KAZUFUMI, SUGA, MORITAKA, TOSAKA, MASAKAZU
Format: Article
Language:Japanese
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 245
container_issue 3
container_start_page 213
container_title Japanese journal of antibiotics
container_volume 57
creator SHIMADA, KAORU
NAKANO, KUNIO
IGARI, JUN
OGURI, TOYOKO
IDEMOTO, HIDEO
MORI, TAKESHI
YOKOUCHI, HIROSHI
YAMAMOTO, MAKOTO
INOUE, HIROSHI
NAKADATE, TOSHIHIDE
SUWABE, AKIRA
OKADA, SHINJI
ASHINO, YUGO
GEJYO, FUMITAKE
OKADA, MASAHIKO
AOKI, NOBUKI
KITAMURA, NOBUKO
SUZUKI, YASUTOSHI
KARASAWA, YASUO
NADATA, KOICHIRO
NADATANI, TATSUO
INAGAWA, HIROKO
KUDO, KOUICHIRO
KOBAYASHI, NOBUYUKI
TANAKA, TSUKASA
KOBAYASHI, HIROYUKI
GOTO, HAJIME
KAWAI, SHIN
TAKEDA, HIDENORI
SUMITOMO, MIDORI
MATSUSHIMA, TOSHIHARU
NIKI, YOSHIHITO
KOHNO, SHIGERU
MIYAZAKI, YOSHITUGU
YANAGIHARA, KATSUNORI
HIRAKATA, YOICHI
MATSUDA, JUNICHI
NASU, MASARU
HIRAMATSU, KAZUFUMI
SUGA, MORITAKA
TOSAKA, MASAKAZU
description From October 2002 to September 2003, we collected the specimen from 476 patients with lower respiratory tract infections in 16 institutions in Japan, and investigated the susceptibilities of isolated bacteria to various antibacterial agents and patients' characteristics. Of 584 strains that were isolated from specimen (mainly from sputum) and assumed to be bacteria causing in inflammation, 578 strains were examined. The breakdown of the isolated bacteria were: Staphylococcus aureus 77, Streptococcus pneumoniae 103, Haemophilus influenzae 95, Pseudomonas aeruginosa (non-mucoid) 61, P. aeruginosa (mucoid) 23, Klebsiella pneumoniae 36, 1 29, etc. Of 77 S. aureus strains, those with 2μg/ml or less of MIC of oxacillin (MPIPC) [methicillin-susceptible S. aureus: MSSA] was 34 strains (44.2%) and those with 4μg/ml or more of MIC of oxacillin (methicillin-resistant S. aureus: MRSA) was 43 strains (55.8%). Against MSSA, imipenem (IPM) and minocycline (MINO) had the most potent antibacterial activity and inhibited the growth of all the strains at 0.25μg/ml. Although clindamycin (CLDM) and aminoglycosides also had the potent activity, the resistant strains against those agents were detected. Cefotiam (CTM) inhibited the growth of all the strains at 1μg/ml without the low sensitive strains. Against MRSA, vancomycin (VCM) showed the most potent activity and inhibited the growth of all the strains at 2μg/ml. Arbekacin (ABK) also showed the relatively potent activity and inhibited the growth of all the strains at 4μg/ml. Carbapenems showed the most potent activities against S. pneumoniae and inhibited the growth of all the strains at 0.25-0.5μg/ml. Cefozopran (CZOP) also had a preferable activity (MIC90: 1μg/ml) and inhibitedthe growth of all the strains at 2μg/ml. In contrast, the resistant strains for cefaclor (CCL), erythromycin (EM), CLDM, and tetracycline (TC) were detected in 50.5%, 76.7%, 50.5%, and 80.6% of all the strains, respectively. Against H. influenzae, LVFX showed the most potent activity and inhibited the growth of 92 of all the strains (96.8%) at 0.063 ug/ml. Tobramycin (TOB) showed the most potent activity against P. aeruginosa (both mucoid and non-mucoid) and inhibited the growth of all the strains at 2μg/ml. The antibacterial activity of CZOP was good and its MIC90 against mucoid and non-mucoid strains was 8 and 16μg/ml, respectively. CZOP and cefpirome (CPR) were the most potent against K. pneumoniae with 0.125μg/ml of MIC90. Also, all the agents gen
doi_str_mv 10.11553/antibiotics1968b.57.213
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_66891007</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>66891007</sourcerecordid><originalsourceid>FETCH-LOGICAL-j218t-7dde83f58e7ad4692aa15a15a744242d4ed7f94009dc1c0c95a4f9eea763c9043</originalsourceid><addsrcrecordid>eNpdkUtP4zAURq3RoKEC_sLIqxGzSPEzdpYhuINRpq5iV2hWkZu4ENQHxOli_j2peCyQrr67OTrSvR8AEKMpxpzTK78bulW3H7om4iyVqykXU4LpNzAhWKYJZ0J8BxNEU5kQIfEpuIixWyGKhSSj4Qc4xZyKVEg2AdEubaEWTl_rUjutLDQzeJ0XTlU6h9qaMnfqBs4q8xcu8hGYOwvvtbuFpblXFayUXegqd6b6B_V8pgqnzdLCG21VbkebMzCfH-3G6cJeEoTI73NwsvabGC7e9xlYzpQrbpPS_NFFXiZP4x1DIto2SLrmMgjfsjQj3mN-HMEYYaRloRXrjCGUtQ1uUJNxz9ZZCF6ktMkQo2fg15v3ud-_HEIc6m0Xm7DZ-F3YH2KdpjLDCIkR_PkOHlbb0NbPfbf1_f_6400jcPcGPMXBP4RPwPdjCZtQf22k5qKmxxhr-YSaR9_XYUdfAXSqgB8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>66891007</pqid></control><display><type>article</type><title>SUSCEPTIBILITIES OF BACTERIA ISOLATED FROM PATIENTS WITH LOWER RESPIRATORY INFECTIOUS DISEASES TO ANTIBIOTICS(2002)</title><source>Alma/SFX Local Collection</source><creator>SHIMADA, KAORU ; NAKANO, KUNIO ; IGARI, JUN ; OGURI, TOYOKO ; IDEMOTO, HIDEO ; MORI, TAKESHI ; YOKOUCHI, HIROSHI ; YAMAMOTO, MAKOTO ; INOUE, HIROSHI ; NAKADATE, TOSHIHIDE ; SUWABE, AKIRA ; OKADA, SHINJI ; ASHINO, YUGO ; GEJYO, FUMITAKE ; OKADA, MASAHIKO ; AOKI, NOBUKI ; KITAMURA, NOBUKO ; SUZUKI, YASUTOSHI ; KARASAWA, YASUO ; NADATA, KOICHIRO ; NADATANI, TATSUO ; INAGAWA, HIROKO ; KUDO, KOUICHIRO ; KOBAYASHI, NOBUYUKI ; TANAKA, TSUKASA ; KOBAYASHI, HIROYUKI ; GOTO, HAJIME ; KAWAI, SHIN ; TAKEDA, HIDENORI ; SUMITOMO, MIDORI ; MATSUSHIMA, TOSHIHARU ; NIKI, YOSHIHITO ; KOHNO, SHIGERU ; MIYAZAKI, YOSHITUGU ; YANAGIHARA, KATSUNORI ; HIRAKATA, YOICHI ; MATSUDA, JUNICHI ; NASU, MASARU ; HIRAMATSU, KAZUFUMI ; SUGA, MORITAKA ; TOSAKA, MASAKAZU</creator><creatorcontrib>SHIMADA, KAORU ; NAKANO, KUNIO ; IGARI, JUN ; OGURI, TOYOKO ; IDEMOTO, HIDEO ; MORI, TAKESHI ; YOKOUCHI, HIROSHI ; YAMAMOTO, MAKOTO ; INOUE, HIROSHI ; NAKADATE, TOSHIHIDE ; SUWABE, AKIRA ; OKADA, SHINJI ; ASHINO, YUGO ; GEJYO, FUMITAKE ; OKADA, MASAHIKO ; AOKI, NOBUKI ; KITAMURA, NOBUKO ; SUZUKI, YASUTOSHI ; KARASAWA, YASUO ; NADATA, KOICHIRO ; NADATANI, TATSUO ; INAGAWA, HIROKO ; KUDO, KOUICHIRO ; KOBAYASHI, NOBUYUKI ; TANAKA, TSUKASA ; KOBAYASHI, HIROYUKI ; GOTO, HAJIME ; KAWAI, SHIN ; TAKEDA, HIDENORI ; SUMITOMO, MIDORI ; MATSUSHIMA, TOSHIHARU ; NIKI, YOSHIHITO ; KOHNO, SHIGERU ; MIYAZAKI, YOSHITUGU ; YANAGIHARA, KATSUNORI ; HIRAKATA, YOICHI ; MATSUDA, JUNICHI ; NASU, MASARU ; HIRAMATSU, KAZUFUMI ; SUGA, MORITAKA ; TOSAKA, MASAKAZU</creatorcontrib><description>From October 2002 to September 2003, we collected the specimen from 476 patients with lower respiratory tract infections in 16 institutions in Japan, and investigated the susceptibilities of isolated bacteria to various antibacterial agents and patients' characteristics. Of 584 strains that were isolated from specimen (mainly from sputum) and assumed to be bacteria causing in inflammation, 578 strains were examined. The breakdown of the isolated bacteria were: Staphylococcus aureus 77, Streptococcus pneumoniae 103, Haemophilus influenzae 95, Pseudomonas aeruginosa (non-mucoid) 61, P. aeruginosa (mucoid) 23, Klebsiella pneumoniae 36, 1 29, etc. Of 77 S. aureus strains, those with 2μg/ml or less of MIC of oxacillin (MPIPC) [methicillin-susceptible S. aureus: MSSA] was 34 strains (44.2%) and those with 4μg/ml or more of MIC of oxacillin (methicillin-resistant S. aureus: MRSA) was 43 strains (55.8%). Against MSSA, imipenem (IPM) and minocycline (MINO) had the most potent antibacterial activity and inhibited the growth of all the strains at 0.25μg/ml. Although clindamycin (CLDM) and aminoglycosides also had the potent activity, the resistant strains against those agents were detected. Cefotiam (CTM) inhibited the growth of all the strains at 1μg/ml without the low sensitive strains. Against MRSA, vancomycin (VCM) showed the most potent activity and inhibited the growth of all the strains at 2μg/ml. Arbekacin (ABK) also showed the relatively potent activity and inhibited the growth of all the strains at 4μg/ml. Carbapenems showed the most potent activities against S. pneumoniae and inhibited the growth of all the strains at 0.25-0.5μg/ml. Cefozopran (CZOP) also had a preferable activity (MIC90: 1μg/ml) and inhibitedthe growth of all the strains at 2μg/ml. In contrast, the resistant strains for cefaclor (CCL), erythromycin (EM), CLDM, and tetracycline (TC) were detected in 50.5%, 76.7%, 50.5%, and 80.6% of all the strains, respectively. Against H. influenzae, LVFX showed the most potent activity and inhibited the growth of 92 of all the strains (96.8%) at 0.063 ug/ml. Tobramycin (TOB) showed the most potent activity against P. aeruginosa (both mucoid and non-mucoid) and inhibited the growth of all the strains at 2μg/ml. The antibacterial activity of CZOP was good and its MIC90 against mucoid and non-mucoid strains was 8 and 16μg/ml, respectively. CZOP and cefpirome (CPR) were the most potent against K. pneumoniae with 0.125μg/ml of MIC90. Also, all the agents generally showed potent activities against M.(B.) catarrhalis and the MIC90 of all drugs were 4μg/ml or less. The approximately half the number (47.5%) of the patients with respiratory infection were aged 70 years or older. As for the incidence by the diseases, bacterial pneumonia and chronic bronchitis were the highest, being noted in 35.7 and 33.8% of all the patients, respectively. The bacteria frequently isolated from the patients with bacterial pneumonia were S. pneumoniae (22.6%). In contrast, S. aureus (16.6%) and P aeruginosa (13.7%) were relatively frequently isolated from the patients with chronic bronchitis. Before the drug administration, the bacteria frequently isolated from all the patients were H. influenzae (24.5%) and S. pneumoniae (24.2%). In comparison of the isolated bacteria by pretreatment agents, P. aeruginosa was relatively frequently isolated from the patients pretreated with cephems or macrolides and H. influenzae was relatively frequently isolated from the patients pretreated with penicillins.</description><identifier>ISSN: 0368-2781</identifier><identifier>EISSN: 2186-5477</identifier><identifier>DOI: 10.11553/antibiotics1968b.57.213</identifier><identifier>PMID: 15376784</identifier><language>jpn</language><publisher>Japan: Japan Antibiotics Research Association</publisher><subject>Anti-Bacterial Agents - pharmacology ; Bacteria - drug effects ; Bacteria - isolation &amp; purification ; Drug Resistance, Bacterial ; Humans ; Respiratory Tract Infections - microbiology ; Time Factors</subject><ispartof>The Japanese Journal of Antibiotics, 2004/06/25, Vol.57(3), pp.213-245</ispartof><rights>Japan Antibiotics Research Association</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15376784$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SHIMADA, KAORU</creatorcontrib><creatorcontrib>NAKANO, KUNIO</creatorcontrib><creatorcontrib>IGARI, JUN</creatorcontrib><creatorcontrib>OGURI, TOYOKO</creatorcontrib><creatorcontrib>IDEMOTO, HIDEO</creatorcontrib><creatorcontrib>MORI, TAKESHI</creatorcontrib><creatorcontrib>YOKOUCHI, HIROSHI</creatorcontrib><creatorcontrib>YAMAMOTO, MAKOTO</creatorcontrib><creatorcontrib>INOUE, HIROSHI</creatorcontrib><creatorcontrib>NAKADATE, TOSHIHIDE</creatorcontrib><creatorcontrib>SUWABE, AKIRA</creatorcontrib><creatorcontrib>OKADA, SHINJI</creatorcontrib><creatorcontrib>ASHINO, YUGO</creatorcontrib><creatorcontrib>GEJYO, FUMITAKE</creatorcontrib><creatorcontrib>OKADA, MASAHIKO</creatorcontrib><creatorcontrib>AOKI, NOBUKI</creatorcontrib><creatorcontrib>KITAMURA, NOBUKO</creatorcontrib><creatorcontrib>SUZUKI, YASUTOSHI</creatorcontrib><creatorcontrib>KARASAWA, YASUO</creatorcontrib><creatorcontrib>NADATA, KOICHIRO</creatorcontrib><creatorcontrib>NADATANI, TATSUO</creatorcontrib><creatorcontrib>INAGAWA, HIROKO</creatorcontrib><creatorcontrib>KUDO, KOUICHIRO</creatorcontrib><creatorcontrib>KOBAYASHI, NOBUYUKI</creatorcontrib><creatorcontrib>TANAKA, TSUKASA</creatorcontrib><creatorcontrib>KOBAYASHI, HIROYUKI</creatorcontrib><creatorcontrib>GOTO, HAJIME</creatorcontrib><creatorcontrib>KAWAI, SHIN</creatorcontrib><creatorcontrib>TAKEDA, HIDENORI</creatorcontrib><creatorcontrib>SUMITOMO, MIDORI</creatorcontrib><creatorcontrib>MATSUSHIMA, TOSHIHARU</creatorcontrib><creatorcontrib>NIKI, YOSHIHITO</creatorcontrib><creatorcontrib>KOHNO, SHIGERU</creatorcontrib><creatorcontrib>MIYAZAKI, YOSHITUGU</creatorcontrib><creatorcontrib>YANAGIHARA, KATSUNORI</creatorcontrib><creatorcontrib>HIRAKATA, YOICHI</creatorcontrib><creatorcontrib>MATSUDA, JUNICHI</creatorcontrib><creatorcontrib>NASU, MASARU</creatorcontrib><creatorcontrib>HIRAMATSU, KAZUFUMI</creatorcontrib><creatorcontrib>SUGA, MORITAKA</creatorcontrib><creatorcontrib>TOSAKA, MASAKAZU</creatorcontrib><title>SUSCEPTIBILITIES OF BACTERIA ISOLATED FROM PATIENTS WITH LOWER RESPIRATORY INFECTIOUS DISEASES TO ANTIBIOTICS(2002)</title><title>Japanese journal of antibiotics</title><addtitle>Jpn. J. Antibiotics</addtitle><description>From October 2002 to September 2003, we collected the specimen from 476 patients with lower respiratory tract infections in 16 institutions in Japan, and investigated the susceptibilities of isolated bacteria to various antibacterial agents and patients' characteristics. Of 584 strains that were isolated from specimen (mainly from sputum) and assumed to be bacteria causing in inflammation, 578 strains were examined. The breakdown of the isolated bacteria were: Staphylococcus aureus 77, Streptococcus pneumoniae 103, Haemophilus influenzae 95, Pseudomonas aeruginosa (non-mucoid) 61, P. aeruginosa (mucoid) 23, Klebsiella pneumoniae 36, 1 29, etc. Of 77 S. aureus strains, those with 2μg/ml or less of MIC of oxacillin (MPIPC) [methicillin-susceptible S. aureus: MSSA] was 34 strains (44.2%) and those with 4μg/ml or more of MIC of oxacillin (methicillin-resistant S. aureus: MRSA) was 43 strains (55.8%). Against MSSA, imipenem (IPM) and minocycline (MINO) had the most potent antibacterial activity and inhibited the growth of all the strains at 0.25μg/ml. Although clindamycin (CLDM) and aminoglycosides also had the potent activity, the resistant strains against those agents were detected. Cefotiam (CTM) inhibited the growth of all the strains at 1μg/ml without the low sensitive strains. Against MRSA, vancomycin (VCM) showed the most potent activity and inhibited the growth of all the strains at 2μg/ml. Arbekacin (ABK) also showed the relatively potent activity and inhibited the growth of all the strains at 4μg/ml. Carbapenems showed the most potent activities against S. pneumoniae and inhibited the growth of all the strains at 0.25-0.5μg/ml. Cefozopran (CZOP) also had a preferable activity (MIC90: 1μg/ml) and inhibitedthe growth of all the strains at 2μg/ml. In contrast, the resistant strains for cefaclor (CCL), erythromycin (EM), CLDM, and tetracycline (TC) were detected in 50.5%, 76.7%, 50.5%, and 80.6% of all the strains, respectively. Against H. influenzae, LVFX showed the most potent activity and inhibited the growth of 92 of all the strains (96.8%) at 0.063 ug/ml. Tobramycin (TOB) showed the most potent activity against P. aeruginosa (both mucoid and non-mucoid) and inhibited the growth of all the strains at 2μg/ml. The antibacterial activity of CZOP was good and its MIC90 against mucoid and non-mucoid strains was 8 and 16μg/ml, respectively. CZOP and cefpirome (CPR) were the most potent against K. pneumoniae with 0.125μg/ml of MIC90. Also, all the agents generally showed potent activities against M.(B.) catarrhalis and the MIC90 of all drugs were 4μg/ml or less. The approximately half the number (47.5%) of the patients with respiratory infection were aged 70 years or older. As for the incidence by the diseases, bacterial pneumonia and chronic bronchitis were the highest, being noted in 35.7 and 33.8% of all the patients, respectively. The bacteria frequently isolated from the patients with bacterial pneumonia were S. pneumoniae (22.6%). In contrast, S. aureus (16.6%) and P aeruginosa (13.7%) were relatively frequently isolated from the patients with chronic bronchitis. Before the drug administration, the bacteria frequently isolated from all the patients were H. influenzae (24.5%) and S. pneumoniae (24.2%). In comparison of the isolated bacteria by pretreatment agents, P. aeruginosa was relatively frequently isolated from the patients pretreated with cephems or macrolides and H. influenzae was relatively frequently isolated from the patients pretreated with penicillins.</description><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Bacteria - drug effects</subject><subject>Bacteria - isolation &amp; purification</subject><subject>Drug Resistance, Bacterial</subject><subject>Humans</subject><subject>Respiratory Tract Infections - microbiology</subject><subject>Time Factors</subject><issn>0368-2781</issn><issn>2186-5477</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><recordid>eNpdkUtP4zAURq3RoKEC_sLIqxGzSPEzdpYhuINRpq5iV2hWkZu4ENQHxOli_j2peCyQrr67OTrSvR8AEKMpxpzTK78bulW3H7om4iyVqykXU4LpNzAhWKYJZ0J8BxNEU5kQIfEpuIixWyGKhSSj4Qc4xZyKVEg2AdEubaEWTl_rUjutLDQzeJ0XTlU6h9qaMnfqBs4q8xcu8hGYOwvvtbuFpblXFayUXegqd6b6B_V8pgqnzdLCG21VbkebMzCfH-3G6cJeEoTI73NwsvabGC7e9xlYzpQrbpPS_NFFXiZP4x1DIto2SLrmMgjfsjQj3mN-HMEYYaRloRXrjCGUtQ1uUJNxz9ZZCF6ktMkQo2fg15v3ud-_HEIc6m0Xm7DZ-F3YH2KdpjLDCIkR_PkOHlbb0NbPfbf1_f_6400jcPcGPMXBP4RPwPdjCZtQf22k5qKmxxhr-YSaR9_XYUdfAXSqgB8</recordid><startdate>200406</startdate><enddate>200406</enddate><creator>SHIMADA, KAORU</creator><creator>NAKANO, KUNIO</creator><creator>IGARI, JUN</creator><creator>OGURI, TOYOKO</creator><creator>IDEMOTO, HIDEO</creator><creator>MORI, TAKESHI</creator><creator>YOKOUCHI, HIROSHI</creator><creator>YAMAMOTO, MAKOTO</creator><creator>INOUE, HIROSHI</creator><creator>NAKADATE, TOSHIHIDE</creator><creator>SUWABE, AKIRA</creator><creator>OKADA, SHINJI</creator><creator>ASHINO, YUGO</creator><creator>GEJYO, FUMITAKE</creator><creator>OKADA, MASAHIKO</creator><creator>AOKI, NOBUKI</creator><creator>KITAMURA, NOBUKO</creator><creator>SUZUKI, YASUTOSHI</creator><creator>KARASAWA, YASUO</creator><creator>NADATA, KOICHIRO</creator><creator>NADATANI, TATSUO</creator><creator>INAGAWA, HIROKO</creator><creator>KUDO, KOUICHIRO</creator><creator>KOBAYASHI, NOBUYUKI</creator><creator>TANAKA, TSUKASA</creator><creator>KOBAYASHI, HIROYUKI</creator><creator>GOTO, HAJIME</creator><creator>KAWAI, SHIN</creator><creator>TAKEDA, HIDENORI</creator><creator>SUMITOMO, MIDORI</creator><creator>MATSUSHIMA, TOSHIHARU</creator><creator>NIKI, YOSHIHITO</creator><creator>KOHNO, SHIGERU</creator><creator>MIYAZAKI, YOSHITUGU</creator><creator>YANAGIHARA, KATSUNORI</creator><creator>HIRAKATA, YOICHI</creator><creator>MATSUDA, JUNICHI</creator><creator>NASU, MASARU</creator><creator>HIRAMATSU, KAZUFUMI</creator><creator>SUGA, MORITAKA</creator><creator>TOSAKA, MASAKAZU</creator><general>Japan Antibiotics Research Association</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>200406</creationdate><title>SUSCEPTIBILITIES OF BACTERIA ISOLATED FROM PATIENTS WITH LOWER RESPIRATORY INFECTIOUS DISEASES TO ANTIBIOTICS(2002)</title><author>SHIMADA, KAORU ; NAKANO, KUNIO ; IGARI, JUN ; OGURI, TOYOKO ; IDEMOTO, HIDEO ; MORI, TAKESHI ; YOKOUCHI, HIROSHI ; YAMAMOTO, MAKOTO ; INOUE, HIROSHI ; NAKADATE, TOSHIHIDE ; SUWABE, AKIRA ; OKADA, SHINJI ; ASHINO, YUGO ; GEJYO, FUMITAKE ; OKADA, MASAHIKO ; AOKI, NOBUKI ; KITAMURA, NOBUKO ; SUZUKI, YASUTOSHI ; KARASAWA, YASUO ; NADATA, KOICHIRO ; NADATANI, TATSUO ; INAGAWA, HIROKO ; KUDO, KOUICHIRO ; KOBAYASHI, NOBUYUKI ; TANAKA, TSUKASA ; KOBAYASHI, HIROYUKI ; GOTO, HAJIME ; KAWAI, SHIN ; TAKEDA, HIDENORI ; SUMITOMO, MIDORI ; MATSUSHIMA, TOSHIHARU ; NIKI, YOSHIHITO ; KOHNO, SHIGERU ; MIYAZAKI, YOSHITUGU ; YANAGIHARA, KATSUNORI ; HIRAKATA, YOICHI ; MATSUDA, JUNICHI ; NASU, MASARU ; HIRAMATSU, KAZUFUMI ; SUGA, MORITAKA ; TOSAKA, MASAKAZU</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-j218t-7dde83f58e7ad4692aa15a15a744242d4ed7f94009dc1c0c95a4f9eea763c9043</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>jpn</language><creationdate>2004</creationdate><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Bacteria - drug effects</topic><topic>Bacteria - isolation &amp; purification</topic><topic>Drug Resistance, Bacterial</topic><topic>Humans</topic><topic>Respiratory Tract Infections - microbiology</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SHIMADA, KAORU</creatorcontrib><creatorcontrib>NAKANO, KUNIO</creatorcontrib><creatorcontrib>IGARI, JUN</creatorcontrib><creatorcontrib>OGURI, TOYOKO</creatorcontrib><creatorcontrib>IDEMOTO, HIDEO</creatorcontrib><creatorcontrib>MORI, TAKESHI</creatorcontrib><creatorcontrib>YOKOUCHI, HIROSHI</creatorcontrib><creatorcontrib>YAMAMOTO, MAKOTO</creatorcontrib><creatorcontrib>INOUE, HIROSHI</creatorcontrib><creatorcontrib>NAKADATE, TOSHIHIDE</creatorcontrib><creatorcontrib>SUWABE, AKIRA</creatorcontrib><creatorcontrib>OKADA, SHINJI</creatorcontrib><creatorcontrib>ASHINO, YUGO</creatorcontrib><creatorcontrib>GEJYO, FUMITAKE</creatorcontrib><creatorcontrib>OKADA, MASAHIKO</creatorcontrib><creatorcontrib>AOKI, NOBUKI</creatorcontrib><creatorcontrib>KITAMURA, NOBUKO</creatorcontrib><creatorcontrib>SUZUKI, YASUTOSHI</creatorcontrib><creatorcontrib>KARASAWA, YASUO</creatorcontrib><creatorcontrib>NADATA, KOICHIRO</creatorcontrib><creatorcontrib>NADATANI, TATSUO</creatorcontrib><creatorcontrib>INAGAWA, HIROKO</creatorcontrib><creatorcontrib>KUDO, KOUICHIRO</creatorcontrib><creatorcontrib>KOBAYASHI, NOBUYUKI</creatorcontrib><creatorcontrib>TANAKA, TSUKASA</creatorcontrib><creatorcontrib>KOBAYASHI, HIROYUKI</creatorcontrib><creatorcontrib>GOTO, HAJIME</creatorcontrib><creatorcontrib>KAWAI, SHIN</creatorcontrib><creatorcontrib>TAKEDA, HIDENORI</creatorcontrib><creatorcontrib>SUMITOMO, MIDORI</creatorcontrib><creatorcontrib>MATSUSHIMA, TOSHIHARU</creatorcontrib><creatorcontrib>NIKI, YOSHIHITO</creatorcontrib><creatorcontrib>KOHNO, SHIGERU</creatorcontrib><creatorcontrib>MIYAZAKI, YOSHITUGU</creatorcontrib><creatorcontrib>YANAGIHARA, KATSUNORI</creatorcontrib><creatorcontrib>HIRAKATA, YOICHI</creatorcontrib><creatorcontrib>MATSUDA, JUNICHI</creatorcontrib><creatorcontrib>NASU, MASARU</creatorcontrib><creatorcontrib>HIRAMATSU, KAZUFUMI</creatorcontrib><creatorcontrib>SUGA, MORITAKA</creatorcontrib><creatorcontrib>TOSAKA, MASAKAZU</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Japanese journal of antibiotics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SHIMADA, KAORU</au><au>NAKANO, KUNIO</au><au>IGARI, JUN</au><au>OGURI, TOYOKO</au><au>IDEMOTO, HIDEO</au><au>MORI, TAKESHI</au><au>YOKOUCHI, HIROSHI</au><au>YAMAMOTO, MAKOTO</au><au>INOUE, HIROSHI</au><au>NAKADATE, TOSHIHIDE</au><au>SUWABE, AKIRA</au><au>OKADA, SHINJI</au><au>ASHINO, YUGO</au><au>GEJYO, FUMITAKE</au><au>OKADA, MASAHIKO</au><au>AOKI, NOBUKI</au><au>KITAMURA, NOBUKO</au><au>SUZUKI, YASUTOSHI</au><au>KARASAWA, YASUO</au><au>NADATA, KOICHIRO</au><au>NADATANI, TATSUO</au><au>INAGAWA, HIROKO</au><au>KUDO, KOUICHIRO</au><au>KOBAYASHI, NOBUYUKI</au><au>TANAKA, TSUKASA</au><au>KOBAYASHI, HIROYUKI</au><au>GOTO, HAJIME</au><au>KAWAI, SHIN</au><au>TAKEDA, HIDENORI</au><au>SUMITOMO, MIDORI</au><au>MATSUSHIMA, TOSHIHARU</au><au>NIKI, YOSHIHITO</au><au>KOHNO, SHIGERU</au><au>MIYAZAKI, YOSHITUGU</au><au>YANAGIHARA, KATSUNORI</au><au>HIRAKATA, YOICHI</au><au>MATSUDA, JUNICHI</au><au>NASU, MASARU</au><au>HIRAMATSU, KAZUFUMI</au><au>SUGA, MORITAKA</au><au>TOSAKA, MASAKAZU</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>SUSCEPTIBILITIES OF BACTERIA ISOLATED FROM PATIENTS WITH LOWER RESPIRATORY INFECTIOUS DISEASES TO ANTIBIOTICS(2002)</atitle><jtitle>Japanese journal of antibiotics</jtitle><addtitle>Jpn. J. Antibiotics</addtitle><date>2004-06</date><risdate>2004</risdate><volume>57</volume><issue>3</issue><spage>213</spage><epage>245</epage><pages>213-245</pages><issn>0368-2781</issn><eissn>2186-5477</eissn><abstract>From October 2002 to September 2003, we collected the specimen from 476 patients with lower respiratory tract infections in 16 institutions in Japan, and investigated the susceptibilities of isolated bacteria to various antibacterial agents and patients' characteristics. Of 584 strains that were isolated from specimen (mainly from sputum) and assumed to be bacteria causing in inflammation, 578 strains were examined. The breakdown of the isolated bacteria were: Staphylococcus aureus 77, Streptococcus pneumoniae 103, Haemophilus influenzae 95, Pseudomonas aeruginosa (non-mucoid) 61, P. aeruginosa (mucoid) 23, Klebsiella pneumoniae 36, 1 29, etc. Of 77 S. aureus strains, those with 2μg/ml or less of MIC of oxacillin (MPIPC) [methicillin-susceptible S. aureus: MSSA] was 34 strains (44.2%) and those with 4μg/ml or more of MIC of oxacillin (methicillin-resistant S. aureus: MRSA) was 43 strains (55.8%). Against MSSA, imipenem (IPM) and minocycline (MINO) had the most potent antibacterial activity and inhibited the growth of all the strains at 0.25μg/ml. Although clindamycin (CLDM) and aminoglycosides also had the potent activity, the resistant strains against those agents were detected. Cefotiam (CTM) inhibited the growth of all the strains at 1μg/ml without the low sensitive strains. Against MRSA, vancomycin (VCM) showed the most potent activity and inhibited the growth of all the strains at 2μg/ml. Arbekacin (ABK) also showed the relatively potent activity and inhibited the growth of all the strains at 4μg/ml. Carbapenems showed the most potent activities against S. pneumoniae and inhibited the growth of all the strains at 0.25-0.5μg/ml. Cefozopran (CZOP) also had a preferable activity (MIC90: 1μg/ml) and inhibitedthe growth of all the strains at 2μg/ml. In contrast, the resistant strains for cefaclor (CCL), erythromycin (EM), CLDM, and tetracycline (TC) were detected in 50.5%, 76.7%, 50.5%, and 80.6% of all the strains, respectively. Against H. influenzae, LVFX showed the most potent activity and inhibited the growth of 92 of all the strains (96.8%) at 0.063 ug/ml. Tobramycin (TOB) showed the most potent activity against P. aeruginosa (both mucoid and non-mucoid) and inhibited the growth of all the strains at 2μg/ml. The antibacterial activity of CZOP was good and its MIC90 against mucoid and non-mucoid strains was 8 and 16μg/ml, respectively. CZOP and cefpirome (CPR) were the most potent against K. pneumoniae with 0.125μg/ml of MIC90. Also, all the agents generally showed potent activities against M.(B.) catarrhalis and the MIC90 of all drugs were 4μg/ml or less. The approximately half the number (47.5%) of the patients with respiratory infection were aged 70 years or older. As for the incidence by the diseases, bacterial pneumonia and chronic bronchitis were the highest, being noted in 35.7 and 33.8% of all the patients, respectively. The bacteria frequently isolated from the patients with bacterial pneumonia were S. pneumoniae (22.6%). In contrast, S. aureus (16.6%) and P aeruginosa (13.7%) were relatively frequently isolated from the patients with chronic bronchitis. Before the drug administration, the bacteria frequently isolated from all the patients were H. influenzae (24.5%) and S. pneumoniae (24.2%). In comparison of the isolated bacteria by pretreatment agents, P. aeruginosa was relatively frequently isolated from the patients pretreated with cephems or macrolides and H. influenzae was relatively frequently isolated from the patients pretreated with penicillins.</abstract><cop>Japan</cop><pub>Japan Antibiotics Research Association</pub><pmid>15376784</pmid><doi>10.11553/antibiotics1968b.57.213</doi><tpages>33</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0368-2781
ispartof The Japanese Journal of Antibiotics, 2004/06/25, Vol.57(3), pp.213-245
issn 0368-2781
2186-5477
language jpn
recordid cdi_proquest_miscellaneous_66891007
source Alma/SFX Local Collection
subjects Anti-Bacterial Agents - pharmacology
Bacteria - drug effects
Bacteria - isolation & purification
Drug Resistance, Bacterial
Humans
Respiratory Tract Infections - microbiology
Time Factors
title SUSCEPTIBILITIES OF BACTERIA ISOLATED FROM PATIENTS WITH LOWER RESPIRATORY INFECTIOUS DISEASES TO ANTIBIOTICS(2002)
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T20%3A20%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=SUSCEPTIBILITIES%20OF%20BACTERIA%20ISOLATED%20FROM%20PATIENTS%20WITH%20LOWER%20RESPIRATORY%20INFECTIOUS%20DISEASES%20TO%20ANTIBIOTICS(2002)&rft.jtitle=Japanese%20journal%20of%20antibiotics&rft.au=SHIMADA,%20KAORU&rft.date=2004-06&rft.volume=57&rft.issue=3&rft.spage=213&rft.epage=245&rft.pages=213-245&rft.issn=0368-2781&rft.eissn=2186-5477&rft_id=info:doi/10.11553/antibiotics1968b.57.213&rft_dat=%3Cproquest_pubme%3E66891007%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-j218t-7dde83f58e7ad4692aa15a15a744242d4ed7f94009dc1c0c95a4f9eea763c9043%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=66891007&rft_id=info:pmid/15376784&rfr_iscdi=true